Jafron Biomedical Co.,Ltd. (SHE:300529)
China · Delayed Price · Currency is CNY 15.56
-0.20 (-1.27%)
Aug 24, 2026, 3:04 PM CST
Jafron Biomedical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Net Income | 525.07 | 532.82 | 820.2 | 436.49 | 889.56 | 1,197 |
Depreciation & Amortization | 118.27 | 119.67 | 127.2 | 94.79 | 73.99 | 54.06 |
Other Amortization | 18.64 | 16.58 | 16.95 | 18.19 | 8.63 | 4.68 |
Loss (Gain) From Sale of Assets | -1.45 | 0.08 | -3.64 | -6.72 | -0.86 | -0.98 |
Asset Writedown & Restructuring Costs | 57.12 | 53.59 | 6.24 | 27.07 | 7.86 | 1.15 |
Loss (Gain) From Sale of Investments | -48.28 | -53.49 | -43.11 | - | -10.51 | -28.72 |
Provision & Write-off of Bad Debts | 1.36 | - | - | - | -1.99 | 6.76 |
Other Operating Activities | 76.61 | 64.26 | 63.35 | 45 | 27.72 | 7.69 |
Change in Accounts Receivable | -10.21 | 10.65 | -8.22 | 277.22 | -7.9 | -110.41 |
Change in Inventory | 44.06 | 38.62 | 41.56 | -37.3 | -152.74 | -75.93 |
Change in Accounts Payable | -183.3 | -58.16 | 0.45 | 52.14 | 60.66 | 203.27 |
Change in Other Net Operating Assets | -14.93 | 3.64 | 35.49 | 10.87 | -8.59 | 8.27 |
Operating Cash Flow | 594.15 | 721.22 | 1,051 | 916.74 | 883.8 | 1,249 |
Operating Cash Flow Growth | -29.27% | -31.38% | 14.64% | 3.73% | -29.26% | 30.49% |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Capital Expenditures | -169.89 | -172.59 | -235.14 | -247.25 | -475.89 | -537.41 |
Sale of Property, Plant & Equipment | 4.75 | 2.86 | 5.34 | 12.6 | 6.91 | 0.99 |
Cash Acquisitions | - | - | - | - | -0.18 | - |
Investment in Securities | -155.55 | 812.88 | -908.45 | -15 | 163.26 | -133.8 |
Other Investing Activities | - | - | 10.78 | - | - | - |
Investing Cash Flow | -320.69 | 643.15 | -1,127 | -249.65 | -305.9 | -670.22 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Short-Term Debt Issued | - | - | 1 | - | - | - |
Long-Term Debt Issued | - | 100.27 | 325.08 | 762.92 | 296.32 | 998.3 |
Total Debt Issued | 100.98 | 100.27 | 326.08 | 762.92 | 296.32 | 998.3 |
Short-Term Debt Repaid | - | -1 | - | - | - | - |
Long-Term Debt Repaid | - | -265.74 | -654.5 | -349.47 | -6.11 | -6.02 |
Total Debt Repaid | -285.63 | -266.74 | -654.5 | -349.47 | -6.11 | -6.02 |
Net Debt Issued (Repaid) | -184.65 | -166.46 | -328.43 | 413.45 | 290.21 | 992.28 |
Issuance of Common Stock | 224.43 | 232.76 | 14.22 | 123.81 | 67.29 | 195.09 |
Repurchase of Common Stock | - | - | -371.28 | -382.58 | -5.19 | -500.13 |
Common Dividends Paid | -427.09 | -643.57 | -340.12 | -561.79 | -729.42 | -531.02 |
Other Financing Activities | -88.6 | 13.94 | 35.78 | -44.8 | 11.19 | 8.94 |
Financing Cash Flow | -475.9 | -563.33 | -989.82 | -451.91 | -365.93 | 165.18 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Foreign Exchange Rate Adjustments | -5.71 | -1.72 | 0.43 | 0.01 | -0.04 | -0 |
Net Cash Flow | -208.16 | 799.32 | -1,066 | 215.19 | 211.93 | 744.37 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 424.25 | 548.63 | 815.85 | 669.49 | 407.91 | 712 |
Free Cash Flow Growth | -34.14% | -32.75% | 21.86% | 64.13% | -42.71% | 18.59% |
Free Cash Flow Margin | 22.21% | 27.27% | 30.47% | 34.83% | 16.37% | 26.61% |
Free Cash Flow Per Share | 0.54 | 0.71 | 1.04 | 0.84 | 0.51 | 0.89 |
Levered Free Cash Flow | 149.73 | 383.66 | 508.63 | 535.7 | 18.61 | 228.28 |
Unlevered Free Cash Flow | 181.9 | 417.11 | 548.45 | 569.66 | 41.13 | 233.85 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash Income Tax Paid | 383.89 | 400.62 | 468.12 | 255.53 | 441.93 | 427.62 |
Change in Working Capital | -153.19 | -12.3 | 63.81 | 301.92 | -110.6 | 7.96 |